N@N

JOEZ, WIP, GHDX, WBMD, PHA, SILU Are Seasonally Ripe To Go Up In the Next Five Weeks

July 4, 2012 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of JOE'S JEANS INC (NASDAQ:JOEZ), SPDR DB INTL GOV INFL-PROT (NYSE:WIP), GENOMIC HEALTH, INC. (NASDAQ:GHDX), WEBMD HEALTH CORP (NASDAQ:WBMD), Pulte Homes Inc. 7.375% Senior Notes due June 1 2046 (NYSE:PHA), Sprott Resource Lending Corporation (AMEX:SILU) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

The following stocks are expected to go Up:

  Symbol  Company                          Expected Return  Odds                 By The Following Date
  JOEZ    JOE'S JEANS INC                  16.11%           75.00% (9 of 12)     Thursday, July 12th 2012
  WIP     SPDR DB INTL GOV INFL-PROT       1.76%            100.00% (5 of 5)     Monday, July 30th 2012
  GHDX    GENOMIC HEALTH, INC.             3.80%            66.67% (4 of 6)      Friday, July 6th 2012
  WBMD    WEBMD HEALTH CORP                1.46%            100.00% (6 of 6)     Friday, July 6th 2012
  PHA     Pulte Homes Inc. 7.375% Senior Notes due June 1 2046  0.77%            100.00% (6 of 6)     Friday, July 6th 2012
  SILU    Sprott Resource Lending Corporation  4.15%            66.67% (4 of 6)      Friday, July 20th 2012

JOE'S JEANS INC (NASDAQ:JOEZ) - Joe's Jeans Inc. engages in the design, development, and marketing of apparel products worldwide. Its product line comprises women's, men's, and children's denim jeans, pants, shirts, sweaters, jackets, and other apparel products under the Joe's brand. The company also offers handbags, clutches, belts, and small leather goods under a license agreement. It sells its products to various retailers, including department stores, specialty stores, and distributors, as well as through its retail stores. As of November 30, 2009, Joe's Jeans Inc. operated two full price retail stores in Chicago, Illinois; and San Francisco, California, as well as four outlet stores in outlet centers. The company was formerly known as Innovo Group Inc. and changed its name to Joe's Jeans Inc. in October 2007. Joe's Jeans Inc. was founded in 1987 and is headquartered in Commerce, California.

SPDR DB INTL GOV INFL-PROT (NYSE:WIP) - SPDR DB International Government InflationProtected Bond ETF

GENOMIC HEALTH, INC. (NASDAQ:GHDX) - Genomic Health, Inc., a life science company, focuses on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. The company offers Oncotype DX breast cancer test, which the multigene expression test that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit, as well as recurrence in early-stage breast cancer. In addition to its adopted Oncotype DX breast cancer test, Genomic Health also offers its Oncotype DX colon cancer test. The company was founded in 2000 and is based in Redwood City, California.

WEBMD HEALTH CORP (NASDAQ:WBMD) - WebMD Health Corp. provides health information services to consumers, physicians and other healthcare professionals, employers, and health plans through its public and private online portals, mobile applications, and health-focused publications in the United States. The companys public portals enable consumers to obtain health and wellness information, including information on specific diseases or conditions; check symptoms; locate physicians; store individual healthcare information; receive periodic e-newsletters on topics of individual interest; and participate in online communities with peers and experts. Its public portals for physicians and healthcare professionals provide access to clinical reference sources; stay abreast of the latest clinical information; learn about new treatment options; earn continuing medical education (CME) credit; and communicate with peers. The company also provides mobile health information applications for use by consumers and physicians. In addition, WebMD Health Corp. provides e-detailing promotion and physician recruitment services, and information services, as well as print services, including the publication of WebMD the Magazine, a consumer magazine distributed to physician office waiting rooms. The public portals sponsors and advertisers include pharmaceutical, biotechnology, medical device, and consumer products companies. The companys private portals enable employers and health plans to provide their employees and members with access to personalized health and benefit information and decision support technology that helps them to make more informed benefit, treatment, and provider decisions. Further, it offers telephonic health coaching services on a per participant basis across an employee or plan population for clients of its private portals. WebMD Health Corp. is headquartered in New York, New York.

Pulte Homes Inc. 7.375% Senior Notes due June 1 2046 (NYSE:PHA) - Pharmacia Corporation, formed in 2000, is primarily involved in the development, manufacturing and sale of pharmaceutical products. Prescription pharmaceuticals is the Company's only business segment and includes general therapeutics, ophthalmology and hospital products, including oncology and diversified therapeutics. The Company also operates several business units that do not constitute reportable business segments. These operating units include, among others, consumer healthcare, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. Due to the size of these operating units, they have been grouped into the Other Pharmaceuticals category. The Company's products are sold throughout the world to a wide range of customers, including pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. In April 2003, the Company completed its merger with and into Pfizer. Pharmacia and Pfizer's combined operations create a research-based pharmaceutical company.

Prescription Pharmaceuticals

The Company's leading prescription products include Celebrex, Xalatan, Genotropin, Camptosar, Detrol LA and Zyvox. Celebrex, a cyclooxygenase-2 (COX-2) specific inhibitor, is a nonsteroidal anti-inflammatory drug, and is used for the treatment of osteoarthritis, adult rheumatoid arthritis, acute pain and primary dysmenorrhea. Celebrex is available in over 70 countries and is co-promoted (or, where required by law, co-marketed) by Pfizer, Inc. in the United States and Europe, and will be co-promoted by Yamanouchi when approved in Japan.

Xalatan, the Company's branded intraocular pressure (IOP) lowering agent, is used in the treatment of open-angle glaucoma and ocular hypertension in patients insufficiently controlled on other medications. During 2001, Xalacom, a fixed combination of Xalatan and the beta-blocker timolol, was approved in Sweden and the European Union, where it is marketed under the name Xalacom. The Company continues to seek approval of Xalcom in the United States after receiving a third approvable letter from the Food and Drug Administration (FDA). Xalcom provides a greater reduction in intraocular pressure.

Genotropin, a recombinant human growth hormone, is used to treat adults with growth hormone deficiency and to treat growth failure in children with growth hormone deficiency. In 2000, Genotropin was also approved for the treatment of growth failure in children with Prader-Willi Syndrome (PWS), and in 2001, it was approved for use with children who were born small for gestational age (SGA) who have not caught up in growth by age two. Genotropin has been granted orphan drug status by the FDA for both PWS and SGA. Adding to the Company's endocrine treatment business, in early 2001, it completed its acquisition of Sensus Drug Development Corporation, which filed a New Drug Application (NDA) with the FDA for pegvisomant, a growth hormone receptor antagonist. Pegvisomant is being reviewed for the treatment of acromegaly, a life-threatening disorder caused by overproduction of growth hormone.

Camptosar, a first-line therapy in metastatic colorectal cancer, is a treatment for colorectal cancer. The product was in-licensed from Yakult Honsha Co. for marketing in the United States. In addition to Camptosar, the Company markets several other oncology drugs. Pharmorubicin is a commonly used treatment for breast cancer in Europe, and is marketed under the trade name Ellence in the United States for the adjuvant treatment of patients with breast cancer. Aromasin, an oral hormonal drug that blocks the production of estrogen, was launched during 2000 in the United States and in key markets in Europe and Latin America as a second-line breast cancer treatment. The Company's subsidiary, Sugen, Inc., has developed proprietary technology platforms to identify small molecule drugs that target specific cellular signal transduction pathways and may have oncological or other therapeutic uses. Pharmacia announced, on February 8, 2002, that it was closing its SU541

Sprott Resource Lending Corporation (AMEX:SILU) -

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641